Open AccessChemoimmunotherapy in urothelial cancer: concurrent or sequential?
Author(s) -
A. Yu. Pavlov,
A. G. Dzidzaria,
Rustem Gafanov,
I. I. Khalil',
A. R. Vashurin
Publication year - 2022
Publication title -
onkourologiâ
Language(s) - English
Resource type - Journals
eISSN - 1996-1812
pISSN - 1726-9776
DOI - 10.17650/1726-9776-2021-17-4-124-128
Subject(s) - chemoimmunotherapy , medicine , urothelial cancer , oncology , immunotherapy , chemotherapy , cancer , bladder cancer , immune checkpoint
Advances in immuno-oncology in the treatment of metastatic urothelial cancer have overturned current perspectives on the treatment of this type of tumor. The success of using Immune checkpoint inhibitors in metastatic urothelial cancer raised the question of effectiveness of immunotherapy added to standard first-line chemotherapy. This review presents data coming from actual studies examining chemotherapy and immunotherapy in urothelial cancer, or a combination of these methods. Ongoing and planned clinical studies should help identify the optimal sequencing, feasibility of combination, and best duration of treatment with checkpoint inhibitors in urothelial cancer.